Theseus Pharmaceuticals, Inc. (THRX)
Market Cap | 177.04M |
Revenue (ttm) | n/a |
Net Income (ttm) | -56.61M |
Shares Out | 43.61M |
EPS (ttm) | -1.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,402,078 |
Open | 4.060 |
Previous Close | 4.060 |
Day's Range | 4.060 - 4.060 |
52-Week Range | 2.050 - 12.370 |
Beta | 3.98 |
Analysts | Strong Buy |
Price Target | 11.75 (+189.41%) |
Earnings Date | Mar 7, 2024 |
About THRX
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development prog... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for THRX stock is "Strong Buy." The 12-month stock price forecast is $11.75, which is an increase of 189.41% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/h/n/press7-2275667.jpg)
Theseus Pharmaceuticals Announces Closing of Tender Offer
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or th...
![](https://cdn.snapi.dev/images/v1/f/q/press8-2250584.jpg)
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered in...
![](https://cdn.snapi.dev/images/v1/3/p/press20-2239074.jpg)
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
![](https://cdn.snapi.dev/images/v1/m/u/press3-2212322.jpg)
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmace...
![](https://cdn.snapi.dev/images/v1/q/4/press5-2206510.jpg)
Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra
MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click...
![](https://cdn.snapi.dev/images/v1/b/4/press16-2206341.jpg)
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between $3...
![](https://cdn.snapi.dev/images/v1/v/z/press1-2206132.jpg)
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of...
![](https://cdn.snapi.dev/images/v1/x/p/press17-2171815.jpg)
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicit...
![](https://cdn.snapi.dev/images/v1/z/f/press6-2155578.jpg)
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of can...
![](https://cdn.snapi.dev/images/v1/o/i/press5-2145326.jpg)
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
CAMBRIDGE, Mass. , Nov. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of canc...
![](https://cdn.snapi.dev/images/v1/b/6/press9-2016789.jpg)
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-varia...
![](https://cdn.snapi.dev/images/v1/x/v/image31-1975855.jpeg)
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/k/m/biotech23-1971172.jpg)
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develo...
![](https://cdn.snapi.dev/images/v1/y/k/press20-1970996.jpg)
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR ...
![](https://cdn.snapi.dev/images/v1/i/j/press12-1913796.jpg)
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
CAMBRIDGE, Mass. , May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients t...
![](https://cdn.snapi.dev/images/v1/v/a/press14-1908627.jpg)
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for b...
![](https://cdn.snapi.dev/images/v1/5/l/press10-1884651.jpg)
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCL...
![](https://cdn.snapi.dev/images/v1/4/p/press11-1855074.jpg)
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus...
![](https://cdn.snapi.dev/images/v1/4/u/conf16-1831989.jpg)
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients...
![](https://cdn.snapi.dev/images/v1/u/h/press18-1814746.jpg)
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients...
![](https://cdn.snapi.dev/images/v1/a/j/press11-1789071.jpg)
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND submi...
![](https://cdn.snapi.dev/images/v1/6/v/press3-1741653.jpg)
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass. , Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients t...
![](https://cdn.snapi.dev/images/v1/a/k/press4-1696251.jpg)
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor ...
![](https://cdn.snapi.dev/images/v1/i/i/press5-1599469.jpg)
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
Potent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity Deep and dura...
![](https://cdn.snapi.dev/images/v1/m/g/press8-1588597.jpg)
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of can...